Literature DB >> 17543674

Treatment of type II endoleak with a transcatheter transcaval approach: results at 1-year follow-up.

Giancarlo Mansueto1, Daniela Cenzi, Alberto Scuro, Leonardo Gottin, Andrea Griso, Andrew A Gumbs, Roberto Pozzi Mucelli.   

Abstract

PURPOSE: This study assessed the feasibility and mid-term outcomes in the treatment of type II endoleak using transcatheter transcaval embolization (TTE).
METHODS: During an 8-month period, 12 patients underwent TTE. After direct transcaval puncture of the aneurysm sac, embolization was performed by injecting thrombin and placing coils. Systemic and intrasac pressures were recorded throughout the entire procedure. Computed tomography (CT) scans were performed at 24 hours, 30 days, 6 months, and 1 year after TTE to evaluate endoleaks and changes in sac diameter. Technical success was defined as the feasibility of the procedure; clinical success was defined as no evidence of leaks during the follow-up evaluation.
RESULTS: TTE was feasible in 11 of 12 patients (technical success 92%). The mean systemic pressure was 117 mm Hg. The mean intrasac pressure before embolization was 75 mm Hg (range, 39 to 125 mm Hg), 16.5 mm Hg (range, 7 to 40 mm Hg) in 10 patients after embolization, and it increased in one patient. CT scans at 24 hours showed stable contrast medium inside the sac in 10 patients. Only minor complications were observed during follow-up. At the 1-year follow-up, no recurrence of leaks was noted, and sac diameter was reduced in 10 of 11 patients. As a result, TTE clinical success was obtained in 10 (83%) of 12 patients.
CONCLUSION: TTE appears to be a feasible technique for the complete exclusion of type II endoleaks. Technical and clinical successes are comparable with other treatment strategies, and TTE should be considered an alternative to direct translumbar puncture of the aneurysm sac.

Entities:  

Mesh:

Year:  2007        PMID: 17543674     DOI: 10.1016/j.jvs.2007.01.063

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

1.  Management of Endoleaks following Endovascular Aneurysm Repair.

Authors:  Sarah B White; S William Stavropoulos
Journal:  Semin Intervent Radiol       Date:  2009-03       Impact factor: 1.513

2.  Transcaval embolization as an alternative technique for the treatment of type II endoleak after endovascular aortic aneurysm repair.

Authors:  Salvatore T Scali; Adrian Vlada; Catherine K Chang; Adam W Beck
Journal:  J Vasc Surg       Date:  2013-01-09       Impact factor: 4.268

Review 3.  Management of Endoleaks.

Authors:  James Chen; S William Stavropoulos
Journal:  Semin Intervent Radiol       Date:  2015-09       Impact factor: 1.513

4.  Type II endoleak repair after endovascular abdominal aortic repair using a computed tomography-guided percutaneous transabdominal approach.

Authors:  Ryo Okabe; Nobuo Morioka; Hideyuki Katayama; Satoru Nakamatsu; Kinya Shirota; Yuhei Saitoh
Journal:  J Vasc Surg Cases       Date:  2015-10-31

5.  Novel Use of Contrast-enhanced Ultrasound in the Pretreatment Planning Prior to Endovascular Repair of Endoleak after Endovascular Aortic Aneurysm Repair in a Patient with Chronic Renal Insufficiency: A Case Report and Literature Review.

Authors:  Jeffrey C Cruz; Kathryn L McGillen; William Pryor; Daniel Esslinger; Benjamin Shin
Journal:  J Med Ultrasound       Date:  2021-04-23

Review 6.  Type II endoleaks: challenges and solutions.

Authors:  Andrew Brown; Greta K Saggu; Matthew J Bown; Robert D Sayers; David A Sidloff
Journal:  Vasc Health Risk Manag       Date:  2016-03-02

Review 7.  Techniques and future perspectives for the prevention and treatment of endoleaks after endovascular repair of abdominal aortic aneurysms.

Authors:  Gianluigi Orgera; Marcello Andrea Tipaldi; Florindo Laurino; Pierleone Lucatelli; Alberto Rebonato; Ioannis Paraskevopoulos; Michele Rossi; Miltiadis Krokidis
Journal:  Insights Imaging       Date:  2019-09-23

Review 8.  Secondary Endoleak Management Following TEVAR and EVAR.

Authors:  Seyed Ameli-Renani; Vyzantios Pavlidis; Robert A Morgan
Journal:  Cardiovasc Intervent Radiol       Date:  2020-08-10       Impact factor: 2.740

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.